Search Results
Your search for it matches 15947 pages
Showing 13051 - 13100Expert Point of View: Mario Sznol, MD
Mario Sznol, MD, of Yale Cancer Center, New Haven, Connecticut, was formal discussant of the MK-3475 presentations at the American Association for Cancer Research (AACR) Annual Meeting. He alluded to all the factors that complicate assays of PD-L1: the disparate nature of the assays themselves, the ...
PD-L1 Studied as Biomarker for Anti–PD-1 Immunotherapy
The anti–PD-1 inhibitor MK-3475 (formerly lambrolizumab) is in late-stage trials for advanced melanoma and is also being studied in other malignancies, including non–small cell lung cancer (NSCLC). An important aspect of Merck’s development program for MK-3475, as well as for other anti–PD-1 agents ...
Expert Point of View: Gary Schwartz, MD
Formal discussant of the LY2835219 trial reported at the American Association for Cancer Research Annual Meeting, Gary Schwartz, MD, of Columbia University School of Medicine, New York, said the drug had “dramatic effects” in estrogen receptor–positive patients. “This drug is highly active in...
ASCO Speaks Out on Release of Medicare Physician Payment Data
The American Society of Clinical Oncology (ASCO) is deeply concerned about [the recent] release of Medicare physician payment data. ASCO is committed to the delivery of high-quality, high-value care for all people with cancer in the United States. This data release solely focuses attention on the...
Maintenance Therapy in Multiple Myeloma
In 2012, three randomized placebo-controlled trials reported a significant prolongation of progression-free survival with lenalidomide (Revlimid) as maintenance therapy for multiple myeloma.1-3 Two of these trials tested lenalidomide maintenance after stem cell transplantation, and one investigated ...
Case Studies: Collaborative Practice in Action
The panel presented two case studies—one on high-dose methotrexate toxicity and one on 5-FU toxicity—as a platform for discussion of considerations, challenges, and interconnected roles of oncologists, nurse practitioners, physician assistants, and clinical pharmacists in safely managing patients...
Collaborative Exchange: The Expanded Access Program and Uridine Triacetate
The panel discussed the various aspects of obtaining a drug such as uridine triacetate through the expanded access program. Ms. Vogel: The expanded access program allows companies to provide patients access to their medicines while the drugs are still in preapproval process, but it is strictly...
Learning More About Expanded Access Programs
The FDA and ASCO have collaborated to create an educational webinar to explain expanded access programs and to clarify the process to access investigational drugs outside a clinical trial. Although it is primarily intended for physicians, the webinar provides valuable information to anyone...
Collaborative Exchange: Timing of Uridine Triacetate
The challenge of deciding when to administer uridine triacetate was explored by the panel. Dr. Schwartzberg: I assume uridine triacetate would work more effectively if given very early; otherwise we would see the same kind of downstream toxicity we see with methotrexate. Dr. Campen: Exactly, but...
Questions Answered About Uridine Triacetate
Q. What is uridine triacetate? A. It is an investigational, orally active prodrug of uridine currently under development as an antidote to overexposure of fluorouracil (5-FU). Although not yet approved by the U.S. Food and Drug Administration, it has been shown to be effective in treating patients...
Collaborative Exchange: Leucovorin and Glucarpidase
The panel discussed the rationale behind the continued use of leucovorin in conjunction with glucarpidase. Dr. Campen: We continue with leucovorin to provide a full basis for recovery of the cells. One important thing to know is that leucovorin should be given separately from glucarpidase because...
Collaborative Exchange: Indications and Dosing
Indications and Dosing of Methotrexate and 5-FU Dr. Campen: The interesting thing about methotrexate is that it has been used for such a long time. You would think there would be a specific dose that would be considered “high dose,” but high dose is actually quite variable. [Dosage] depends on the...
Meet the Panel
Based on a roundtable discussion conducted at the first annual JADPRO Live 2014 educational symposium in St. Petersburg, Florida, this supplement centers on strategies for preventing and treating severe side effects associated with methotrexate and fluorouracil (5-FU) from the unique perspectives...
CE Activity Instructions
CE is available on May 1, 2014 and expires on May 1, 2015. A continuing education activity for physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other allied health professionals specializing in the field of oncology. This activity is supported by an unrestricted...
ASCO Issues Two New Guidelines on Treating Patients With Advanced, HER2-Positive Breast Cancer
ASCO recently issued two clinical practice guidelines on treating women with advanced, HER2-positive breast cancer. The first guideline lists the appropriate systemic therapies for women newly diagnosed with advanced disease and those whose early-stage disease progressed to advanced cancer. The...
Food and Drug Interactions Could Reduce Effectiveness of Oral Chemotherapy
Oral chemotherapy agents are associated with drug and food interactions that can significantly reduce the effectiveness of oral chemotherapy and possibly result in harm to patients, according to a study in the Journal of Oncology Practice. It is important therefore, according to the study’s...
Genitourinary Toxicity More Likely With Stereotactic Body Radiotherapy Than With Intensity-Modulated Radiotherapy
A retrospective analysis of patients with prostate cancer receiving primary treatment with either stereotactic body radiation therapy or intensity-modulated radiation therapy found that those receiving stereotactic body radiotherapy had greater rates of genitourinary toxicity during 2-year...
Can Empathy Really Be Taught?
In an op-ed article in The New York Times (February 27, 2014) about the challenges of designing training courses to help physicians communicate more effectively with patients about important topics such as end-of-life care, Timothy D. Gilligan, MD, and Mikkael A. Sekeres, MD, of the Cleveland...
Don’t Always Expect Questions From Patients About Prognosis
Although most patients want to know about the potential outcome of their disease and whether treatment is likely to have a significant impact on it, the information needs of patients and how best to fulfill those needs are very variable, Walter F. Baile, MD, told The ASCO Post. Dr. Baile is...
Breaking Bad News Badly Can Add to Upset
When the prognosis is poor, breaking the bad news badly can exacerbate the distress experienced by cancer patients and their families. A lack of sensitivity to patient and family emotions and not being attuned to how individual patients would prefer to be informed about their prognoses can result...
New p53-Dependent Gene Cooperates With p53 in Tumor-Suppressor Functions
The TP53 tumor-suppressor gene influences genomic stability, apoptosis, autophagy, response to stress, and DNA damage, and identification of new p53-target genes could help elucidate mechanisms through which p53 controls cell integrity and response to damage. As reported in Journal of the National...
DNA Repair Pathway Recombination Proficiency Score Correlates With Tumor Sensitivity to Chemotherapy
As reported in Science Translational Medicine, Pitroda and colleagues developed a recombination proficiency score that measures the efficiency of DNA repair pathways in the context of cancer therapy aimed at generating DNA damage. The score is based on expression levels of four genes involved in...
IL-17A Promotes and GM-CSF Suppresses Circulating Tumor Cells and Metastasis in Colorectal Cancer
In a study of the roles of interleukin (IL)-17A and circulating tumor cells in colorectal cancer metastasis, Tseng and colleagues measured mesenteric circulating tumor cells according to colorectal cancer stage in patients and assessed the interaction of circulating tumor cells and IL-17A in a...
Inactivation of E3 Ubiquitin Ligase Cbl-b Allows Natural Killer Cells to Control Metastases
New therapeutic approaches to blocking inhibitory pathways of the immune system have raised hopes that such treatments might thwart development of metastases. In a study in Nature, Paolino and colleagues have shown that genetic deletion of the E3 ubiquitin ligase Cbl-b (casitas B-lineage...
PPAR-δ/β Overexpression Increases Colon Tumorigenesis
Although it is known that nuclear receptor peroxisome proliferator-activated receptor-δ/β (PPAR-d) is upregulated in colorectal cancer, the role of PPAR-d in tumorigenesis remains uncertain. In a study reported in Journal of the National Cancer Institute, Zuo and colleagues developed a mouse model...
Learning to Live in the Moment
I’ve been health conscious all my life. I have never smoked, I eat a healthy diet, and I have maintained a near-daily exercise routine since I was 20. I’m also steadfast about keeping yearly medical checkups and screenings. So when I felt a sharp, lightning-bolt of pain that went from the top of my ...
ASCO Cofounder Jane Cooke Wright, MD, Defied Racial/Gender Barriers and Helped Usher in the Modern Age of Chemotherapy
When Jane Cooke Wright, MD, met with six other oncologists at the Edgewater Beach Hotel in Chicago on April 9, 1964, to discuss the creation of American Society of Clinical Oncology, the first medical society dedicated to bringing patient-oriented issues to clinical oncology, the Civil Rights Act...
ASCO’s Visionary Founders
On April 9, 1964, seven physicians—Jane Cooke Wright, MD, FASCO; Arnoldus Goudsmit, MD, PhD; Fred J. Ansfield, MD, FASCO; Harry F. Bisel, MD, FASCO; Herman H. Freckman, MD, FASCO; Robert W. Talley, MD, FASCO; and William Wilson, MD, FASCO—met for lunch at the Edgewater Beach Hotel in Chicago. They...
The Camaraderie of ASCO
Oncologists are occupied with an unusual kind of medicine, and, as a result, we are exposed to enormous personal stress and strain, because patients we care for are profoundly sick with potentially fatal diseases. As a group, we deal with the possible mortality of those for whom we are responsible...
The Consequence Is Cure
My Presidency was the first year that the Annual Meeting hit 10,000 attendees, which at the time we thought was a huge number—it seemed that we’d hit the ceiling. It was about 9 years after we published the results from our study of combination chemotherapy (MOPP) in the treatment of advanced...
Journal of Clinical Oncology
During my Presidency, we decided to increase ASCO’s size to give clinical investigators a better position in the medical world. To that end, I decided that the Society needed its own journal. At that time, we sent our papers to Blood or Cancer Research, where, in my estimation, they received poor...
Science vs Practice
My year as President was a busy one. Aside from continuing my research and directing the activities of the National Surgical Adjuvant Breast and Bowel Project, I was drowned by the vast amount of information that was sent to me by ASCO headquarters. At the onset of my Presidency, I discovered...
AACR–ASCO Transition
My Presidency was a transitional year; it was the first time that ASCO had a meeting separate from the American Association for Cancer Research. Since ASCO was thought to be simply a science-light organization that focused solely on clinical trials, the pressure was on to establish an independent...
Cancer Prevention
One highlight of serving as ASCO President is working with the outstanding staff—to name just a few, Executive Vice President Charles M. Balch, MD; Chief Operating Officer Ron Beller, PhD; Jean Colvard; Roseanna Thoman; and all the Department heads. During my Presidency, we undertook some very...
Multidisciplinary Interactions
As my Presidency gradually fades into the past, it is sobering to reminisce on how exciting it was. ASCO is a great organization with an amazing staff and a solid mission. Chairing the Board meetings was clearly a highlight of my Presidency because of the vast talent and collective wisdom that is...
One Community
My Presidential theme was One Community. I think that theme continues to express much of our goal in oncology, which is to make sure that all members of the cancer care team work together—oncologists, nurses, scientists, nutritionists, psychologists, social workers, administrators, and others. I...
Personalizing Cancer Care
Durng my Presidency we completely revamped the way the ASCO Board of Directors works by creating various subcommittees and a much more deliberate strategic planning process. In effect, the Board members took more ownership of ASCO’s agenda, planning the future of the Society rather than dealing...
Collaborating to Conquer Cancer
Serving as ASCO’s President was one of the most exciting years of my professional career. Although that year presented a number of challenges, it also marked a number of accomplishments, including a record number of new ASCO members, which then reached more than 30,000 in 122 countries (today,...
The Leukemia & Lymphoma Society Surpasses $1 Billion Investment in Blood Cancer Research
The Leukemia & Lymphoma Society (LLS) has announced that it has passed the $1 billion mark in research investment, a significant milestone in the cancer research landscape as the Society continues its 65-year pursuit of advancing breakthrough therapies, finding cures, and ensuring access to...
Duquesne University Awarded $1.4 Million NIH Grant
Duquesne University’s newly established biomedical engineering initiative has received a $1.4 million, 5-year grant from the National Institutes of Health’s National Cancer Institute to detect, capture and analyze circulating melanoma cells. John Viator, MD, Biomedical Engineering Program Director...
An Oncologic Surgeon Discusses the Pros and Cons of Pursuing a Business Degree
Is pursuing a Master of Business Administration (MBA) degree a good idea for ambitious surgical oncologists who want to advance their careers? The ASCO Post recently spoke with Martin J. Heslin, MD, MSHA, Chief, Section of Surgical Oncology, University of Alabama at Birmingham (UAB) Medical Center, ...
SIDEBAR: Research Groups in South America
Although cancer research in South America has been largely led by the pharmaceutical industry, a number of independent research groups are active in the region. Peru: GECOPERU and INEN The Peruvian Oncology Clinical Studies Group (Grupo de Estudios Clínicos Oncológicos Peruano, or GECOPERU...
A Vision of Independent Clinical Research in South America
Clinical research is vital for the development and improvement of methods designed to prevent and treat cancer. The majority of clinical trials take place in the developed world through sponsored pharmaceutical research companies.1 The corresponding lack of research in developing countries results...
Ramucirumab for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
On April 21, 2014, ramucirumab (Cyramza) was approved for use as a single agent in the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing...
Connecting to ASCO Through the State Affiliate Council
ASCO’s State Affiliate Council is composed of the State Society Presidents and/or designated physician Council Representatives as well as the Executive Directors of each state and/or regional oncology society. The Council convened in late February to address the most relevant issues affecting...
Schwartz Center Rounds® Programs Foster Clinical Teamwork and Enhance Patient Care
In the fall of 1994, 40-year-old Kenneth B. Schwartz, a health-care lawyer, was diagnosed with lung cancer. Radiation and chemotherapy failed to stop progression of the disease, and 10 months later he died. During his treatment, Mr. Schwartz wrote about the ordeal of coming to grips with the...
Ofatumumab Plus Chlorambucil for Previously Untreated CLL in Patients Not Treatable With Fludarabine-Based Regimens
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 17, 2014, ofatumumab (Arzerra) received regular approval...
Personalizing Outreach to Address Asian Cancer Health Disparities
In an effort to reduce cancer health disparities among Asian Americans, UC Davis Comprehensive Cancer Center now offers individual, in-language education and culturally sensitive materials for every Asian American cancer patient. New brochures and 5-minute videos were debuted during the National...
Improving Quality of Life in Cancer Survivors
The number of cancer survivors has been steadily increasing in recent years. According to the Ministry of Health National Cancer Registry, in 2010 there were 254,000 cancer survivors in Israel (3.3% of the population) compared with 15,700 (0.4% of the population, P < .005) in 1975.1 Forty years...
Ongoing Clinical Trials Actively Recruiting Patients With Ovarian or Cervical Cancers
The information contained in this Clinical Trials Resource Guide includes details of actively recruiting clinical studies of patients with gynecologic and breast cancers. It also includes the Family Caregiver Palliative Care Intervention study, which is investigating interventions to support...
